statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Inventiva Advances Lanifibranor Trial with Promising Data

Inventiva (IVA) has released an update. Inventiva reports strong progress in its NATiV3 Phase III clinical trial for lanifibranor, with over 80% en...

FY2025 Earnings Forecast for Inventiva S.A. (NASDAQ:IVA) Issued By HC Wainwright

Inventiva S.A. (NASDAQ:IVA - Free Report) - Equities research analysts at HC Wainwright increased their FY2025 earnings per share estimates for shares of Inventiva in a report issued on Monday...

Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F

Daix (France), Long Island City (New York, United States), April 3, 2024 Inventiva (Euronext Paris and Nasdaq: IVA) (the Company ), a clinical-stage biopharmaceutical company focused on the...

Buy Rating Affirmed: Inventiva's Progress and Promise in Lanifibranor's Clinical Trials

Analyst Ed Arce of H.C. Wainwright maintained a Buy rating on Inventiva (IVA Research Report), retaining the price target of $22.00. Ed Arce has...

Brokerages Set Inventiva S.A. (NASDAQ:IVA) Price Target at $15.67

Inventiva S.A. (NASDAQ:IVA - Get Free Report) has been given an average recommendation of "Buy" by the eight brokerages that are covering the firm, MarketBeat.com reports. Eight investment analysts...

Full Year 2023 Inventiva SA Earnings Call Transcript

Inventiva SA (IVA, $3.67) price exceeded its 50-day Moving Average on March 28, 2024

This price move could indicate a change in the trend, and may be a sell signal for investors...

Inventiva announces the nomination of Andre Turenne as Director

Daix (France), Long Island City (New York, United States), March 28, 2024 Inventiva (Euronext Paris and Nasdaq: IVA) (the Company ), a clinical-stage biopharmaceutical company focused on the...

Inventiva S.A. (IVA) Q4 2023 Earnings Call Transcript

Inventiva S.A. (IVA) Q4 2023 Earnings Call Transcript...

Inventiva SA is a clinical-stage biopharmaceutical company, which focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis, or NASH, and other diseases with significant unmet medical need. It owns an in-house drug-discovery platform that develops internal oncology and fibrosis discovery pipeline with approaches centered on transcription factors, epigenetics targets, and nuclear receptors. The company was founded by Pierre Broqua and Frédéric Cren on October 27, 2011 and is headquartered in Daix, France.

Volume	28,047.00
52-Wk High	$4.75
52-Wk Low	$2.15

IVA Inventiva - ADR

About

Feed

News

Sentiment

Earnings

Fundamentals